NCT03410979

A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy Subjects

A 2-part, Randomized, Double-blind, Placebo-controlled, Sequential Group, Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of GLPG2737 in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 79 (actual)
• Sponsor: Galapagos NV · Industry
• Sex: Male
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

This study is a first-in-human (FIH), Phase I, single center, randomized, double-blind, placebo-controlled, sequential group study in healthy male subjects to assess the safety, tolerability and PK of single ascending oral doses of GLPG2737 and multiple ascending oral doses of GLPG2737 administered for 14 days.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	GLPG2737 single dose	GLPG2737 oral suspension, single ascending doses
DRUG	Placebo single dose	Placebo, oral suspension.
DRUG	GLPG2737 multiple dose	GLPG2737 oral suspension, multiple ascending doses, daily for 14 days.
DRUG	GLPG2737 multiple dose	Placebo, oral suspension, daily for 14 days

Timeline

• Start date: 2016-11-25
• Primary completion: 2017-08-15
• Completion: 2017-08-15
• First posted: 2018-01-25
• Last updated: 2018-01-25

Locations

1 site across 1 country: Netherlands